Goldman Sachs’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Goldman Sachs’s Portfolio STSA Stock Details STSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10,109	Closed	-$42K	–	6708
2022 Q2	$42K	Sell	10,109 -26	-0.3%	-$92	﹤0.01%	6065
2022 Q1	$39K	Sell	10,135 -198	-2%	-$892	﹤0.01%	6314
2021 Q4	$46K	Sell	10,333 -800	-7%	-$4.06K	﹤0.01%	6280
2021 Q3	$52K	Sell	11,133 -10,797	-49%	-$57.2K	﹤0.01%	6041
2021 Q2	$155K	Buy	21,930 +4,721	+27%	+$25.5K	﹤0.01%	5840
2021 Q1	$102K	Sell	17,209 -14,218	-45%	-$86.1K	﹤0.01%	5842
2020 Q4	$145K	Buy	+31,427	New	+$135K	﹤0.01%	5196
2020 Q3	–	Sell	-29,781	Closed	-$857K	–	5604
2020 Q2	$857K	Buy	+29,781	New	+$689K	﹤0.01%	4062
2019 Q4	–	Sell	-27,500	Closed	-$413K	–	5462
2019 Q3	$413K	Buy	+27,500	New	+$427K	﹤0.01%	4532

Other funds holding STSA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs's STSA Position: Q3 2022 in Review

Goldman Sachs sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q3 2022, closing a stake of 10,109 shares — an estimated $42K sold.

Goldman Sachs first reported a position in STSA in Q3 2019 and held it in 9 quarters. The position peaked at $857K in Q2 2020. 41 funds tracked by Wall St. Rank hold STSA as of Q3 2022.

Goldman Sachs reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Goldman Sachs sold 10,109 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $42K.
Goldman Sachs first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 9 quarters.
Goldman Sachs's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $857K in Q2 2020.
41 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on Goldman Sachs's 13F filing for Q3 2022, filed 14 Nov 2022.